Suppr超能文献

大隐静脉移植血管病变、病理生理学、预防及治疗:文献综述

Saphenous vein graft disease, pathophysiology, prevention, and treatment. A review of the literature.

作者信息

Guida Gustavo, Ward Alex O, Bruno Vito D, George Sarah J, Caputo Massimo, Angelini Gianni D, Zakkar Mustafa

机构信息

Faculty of Health Sciences, Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol, UK.

Department of Cardiovascular Sciences, Clinical Sciences Wing, University of Leicester, Glenfield Hospital, Leicester, England.

出版信息

J Card Surg. 2020 Jun;35(6):1314-1321. doi: 10.1111/jocs.14542. Epub 2020 Apr 30.

Abstract

BACKGROUND

The saphenous vein remains the most frequently used conduit for coronary artery bypass grafting, despite reported unsatisfactory long-term patency rates. Understanding the pathophysiology of vein graft failure and attempting to improve its longevity has been a significant area of research for more than three decades. This article aims to review the current understanding of the pathophysiology and potential new intervention strategies.

METHODS

A search of three databases: MEDLINE, Web of Science, and Cochrane Library, was undertaken for the terms "pathophysiology," "prevention," and "treatment" plus the term "vein graft failure."

RESULTS

Saphenous graft failure is commonly the consequence of four different pathophysiological mechanisms, early acute thrombosis, vascular inflammation, intimal hyperplasia, and late accelerated atherosclerosis. Different methods have been proposed to inhibit or attenuate these pathological processes including modified surgical technique, topical pretreatment, external graft support, and postoperative pharmacological interventions. Once graft failure occurs, the available treatments are either surgical reintervention, angioplasty, or conservative medical management reserved for patients not eligible for either procedure.

CONCLUSION

Despite the extensive amount of research performed, the pathophysiology of saphenous vein graft is still not completely understood. Surgical and pharmacological interventions have improved early patency and different strategies for prevention seem to offer some hope in improving long-term patency.

摘要

背景

尽管有报道称大隐静脉长期通畅率不尽人意,但它仍是冠状动脉旁路移植术中最常用的血管 conduit。三十多年来,了解静脉移植物失败的病理生理学并试图提高其使用寿命一直是一个重要的研究领域。本文旨在综述目前对病理生理学的理解以及潜在的新干预策略。

方法

对三个数据库(MEDLINE、科学网和考克兰图书馆)进行检索,检索词为“病理生理学”“预防”“治疗”以及“静脉移植物失败”。

结果

大隐静脉移植物失败通常是四种不同病理生理机制的结果,即早期急性血栓形成、血管炎症、内膜增生和晚期加速动脉粥样硬化。已经提出了不同的方法来抑制或减轻这些病理过程,包括改良手术技术、局部预处理、外部移植物支撑和术后药物干预。一旦移植物失败发生,可用的治疗方法要么是手术再次干预、血管成形术,要么是为不符合任何一种手术条件的患者保留的保守药物治疗。

结论

尽管进行了大量研究,但大隐静脉移植物的病理生理学仍未完全了解。手术和药物干预改善了早期通畅率,不同的预防策略似乎为提高长期通畅率带来了一些希望。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验